%20BIANCO.png)
Pipeline
Our compounds target components of the solid tumor microenvironment to foster anti-cancer immune response enhancing the recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors.
SEMA3A
LVB 001
Mutant SEMA3A
is a PlexinA4-selective superagonist for cancer treatment that normalizes tumor vasculature and induces tumor-restraining CAF polarization.
PlexinA4
is a semaphorin receptor that negatively controls cytotoxic T lymphocytes migration in cancer.
LVB 002
PlexinA4
SLC4A4
LVB 003
SCL4A4
is a bicarbonate transporter that induces bicarbonate uptake by cancer cells and increases TME acidity.
Undisclosed
LVB-004
Undisclosed
P2Y6
LVB-005
P2Y6
Cytidine deaminase (CDA) is an enzyme of the pyrimidine salvage pathway that is involved in extracellular release of UTP and UDP. CDA-positive cancer cells recruit P2Y6-positive macrophages and sustain their immunosuppressive activity via UDP and UTP release.
Undisclosed
LVB-006
Undisclosed
Our approach aims at reprogramming the solid tumor microenvironment to unlock the full potential of cancer immunotherapy.
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field